Navigation Links
Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline
Date:5/28/2009

NEW YORK, May 28 /PRNewswire/ -- Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly owned subsidiary of Kyowa Hakko Bio Co., Ltd., (Kyowa), has announced it has completed GRAS (Generally Recognized As Safe) self-affirmation for the novel brain health ingredient Cognizin(R) Citicoline.

Cognizin(R) is a branded form of Citicoline, a natural nutrient found in every cell of the body. Citicoline provides an essential nutrient for cells -- particularly brain cells. Cognizin(R) supports brain health in several ways.

First, brain imaging technology has shown that Cognizin(R) helps increase brain energy. * Second, Cognizin(R) provides essential structural components for synthesizing brain cell membranes, which may help facilitate brain cell communication. * Lastly, Cognizin(R) helps support the formation of several brain nutrients that regulate cognitive function. * Cognizin(R) has been the subject of several human clinical trials.

The most recent trial studied the effect of Cognizin(R) on healthy middle-aged adults. Using the latest brain scanning technology, researchers at the Harvard-associated Brain Imaging Center at McLean Hospital in Boston, observed increases in brain activity among people who had taken Cognizin(R) for six weeks, particularly when individuals performed tasks that required sustained attention or memory.

Because Cognizin(R) helps make more energy available to brain cells, they are better able to perform their daily tasks. Cell membranes are synthesized and maintained. Vital brain nutrients are produced and electrical impulses are generated.

These activities may help improve the overall functioning of the brain, which is why Cognizin(R) may significantly increase the ability to focus, concentrate, and make decisions.*

Cognizin(R) Citicoline or CDP-choline will be marketed by Kyowa Hakko USA as a food ingredient in the United States for use at levels of 250 mg/serving in various food products, beverages and beverage bases, breakfast cereals, chewing gum, dairy product analogs, frozen dairy desserts, grain products and pastas, hard candies, milk and milk products, processed fruits and fruit juices, and soft candy.

In addition to Cognizin(R) brand Citicoline, Kyowa is the maker of other leading branded ingredients including Hydrafend(TM) Hyaluronic Acid, Lumistor(R) L-Hydroxyproline, Kyowa CoQ10(R), Setria(R) Glutathione and Sustamine(TM) Alanyl Glutamine. Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

For more information about Cognizin(R) brand Citicoline, contact Kyowa Hakko USA at 212.319.5353 or visit the web site at www.Cognizin.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


'/>"/>
SOURCE Kyowa Hakko USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Announces New Vice President of Marketing
2. Valeant Announces Increase to Securities Repurchase Program
3. Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoints NextRx Subsidiaries
4. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
5. CenTrak Announces 16 New Deployments This Year: Company Installs Over 6 Million Square Feet in Last Six Months
6. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
7. WellPoint Announces Appearances at Upcoming Conferences
8. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
9. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
10. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
11. gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStreams Executive Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology: